In hematologic malignancy treatment, AUTX‐703 [394] targets KAT2A and KAT2B, currently in Phase I studies in myelodysplastic syndromes and acute myeloid leukemia patients (NCT06846606), while KT‐253 [395], as an MDM2 protein degrader, restores p53 tumor suppressor function by inducing selective MDM2 protein degradation, currently in Phase I clinical evaluation in multiple blood cancers (NCT05775406). Here, MDM2 is linked to myelodysplastic syndrome.